BEDFORD, Mass., Nov. 7, 2011 /PRNewswire/ -- Hologic, Inc. (Hologic or the Company) (Nasdaq: HOLX), a leading developer, manufacturer and supplier of premium diagnostics products, medical imaging systems and surgical products dedicated to serving the healthcare needs of women, will showcase a comprehensive suite of gynecologic surgical products at AAGL 40th Annual Global Congress of Minimally Invasive Gynecology, November 6-10, 2011, at the Westin-Diplomat Hotel in Hollywood, Florida.
Hologic's GYN surgical products provide innovative minimally invasive alternatives for physicians to make available to women who often do not realize they have options to traditional surgeries such as tubal ligation and hysterectomy.
"Hologic and our OB/GYN customers strive to educate women about options to traditional surgery that do not require incisions, lengthy hospital stays or the unnecessary removal of major organs," said Shacey Petrovic, Vice President of Marketing for GYN Surgical Products at Hologic. "Demand for minimally invasive procedures continues to climb as an increasing number of gynecologists perform procedures in-office, resulting in shorter patient recovery times and significant cost benefits."
At this year's AAGL Congress, Hologic is showcasing three new products and a new partnership agreement.
The Hologic Aquilex fluid control system is designed for high aspiration outflow procedures such as the Hologic MyoSure hysteroscopic tissue removal system, making it the highest-performing fluid management system with integrated vacuum capability on the market. The Aquilex system is designed to simplify hysteroscopy through easy set-up and minimized risk of inaccurate deficit readings. Its high inflow rate capability and integrated suction design are intended to rapidly achieve and hold constant distention independent of hysteroscope diameter to improve visualization of the uterine cavity throughout the procedure.
The Company will have on display a new simulation system, GyneSim, a platform for realistic teaching and training of transcervical procedures. The GyneSim is optimized for the MyoSure system and will be used for physician education, resident training and sales training. Hologic representatives will be available at the Congress to offer hands-on, virtual reality training demonstrations.
In October, Hologic received CE marking approval for the next generation of the Adiana permanent contraception (Adiana) system. Adiana is a minimally invasive procedure that requires no incisions and can be performed in the comfort of the doctor's office using local anesthesia. It is designed to provide women with an alternative to traditional, surgical means of permanent contraception such as tubal ligation. Featuring a biocompatible radiopaque matrix, CE marking approval allows Hologic to market Adiana permanent contraception with the radiopaque matrix in the 27 countries of the European Union and three of the four member states of the European Free Trade Association.
AAGL 2011 also marks the announcement of Hologic's strategic partnership agreement with KARL STORZ Endoscopy America, Inc. giving Hologic's GYN Surgical division the exclusive distribution rights to a new video platform and hysteroscopic instrumentation to further the adoption of minimally-invasive procedures in the office setting. The new agreement enhances the existing Hologic THS tower-free hysteroscopy system and will enable physicians to perform the NovaSure endometrial ablation, Adiana, and MyoSure procedures in their offices.
"KARL STORZ is a leader in endoscopy and visualization with a reputation for quality products, strong key opinion leader relationships, and a dedication to the development of innovative endoscopic surgical technologies," said Steve Williamson, Senior Vice President and General Manager, GYN Surgical Products at Hologic. "This partnership agreement enables Hologic to continue the delivery of best-in-class physician training and increase the accessibility of in-office procedures for women."
In 2011 Hologic celebrated the 10-year anniversary of the NovaSure system, a simple, one-time, five-minute procedure for heavy menstrual bleeding, or menorrhagia. Heavy periods affect one in five women and often begin when women reach ages in their 30s and 40s. Since 2001, more than 1.5 million women have been treated with the NovaSure procedure to reduce or eliminate menstrual bleeding, without hormones or an invasive hysterectomy.
For more information about Hologic's gynecologic surgical products, presentations and sessions at AAGL, please visit booth 411.
About Hologic, Inc.
Hologic, Inc. is a leading developer, manufacturer and supplier of premium diagnostics products, medical imaging systems and surgical products dedicated to serving the healthcare needs of women. Hologic's core business units are focused on breast health, diagnostics, GYN surgical and skeletal health. Hologic provides a comprehensive suite of technologies with products for mammography and breast biopsy, breast Magnetic Resonance Imaging, radiation treatment for early-stage breast cancer, cervical cancer screening, treatment for menorrhagia and uterine fibroids, permanent contraception, osteoporosis assessment, preterm birth risk assessment, mini C-arm for extremity imaging and molecular diagnostic products including HPV and reagents for a variety of DNA and RNA analysis applications.
Forward-Looking Statement Disclaimer
This News Release may contain forward-looking information that involves risks and uncertainties, including statements about the use of the NovaSure system, the THS tower-free hysteroscopy system and the Aquiflex system. There can be no assurance the systems will achieve the benefits described herein and that such benefits will be replicated in any particular manner with respect to an individual patient as the actual effect of the use of these systems can only be determined on a case-by-case basis depending on the particular circumstances and patient in question. Hologic expressly disclaims any obligation or undertaking to release publicly any updates or revisions to the data or statements presented herein to reflect any change in the Company's expectations or any change in events, conditions or circumstances on which any such data or statements are based. Certain factors that could adversely affect the Company's business and prospects are described in Hologic filings with the Securities and Exchange Commission.
Hologic, Adiana, Aquilex, MyoSure, NovaSure, THS and Total Office Solution are trademarks and/or registered trademarks of Hologic, Inc., and/or its subsidiaries in the United States and/or other countries.
Publicity and Advertising Specialist